Markus Wartmann

Medicine · Health Sciences

45h-index9.0kcitations202works27.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(61), Synthetic Organic Chemistry Methods(31), Fibroblast Growth Factor Research(30), Kruppel-like factors research(27), Epigenetics and DNA Methylation(26)

Publications202 total

Fragment-based discovery reveals unprecedented ligandability and enables direct targeting of the melanoma oncogene MITF
Figshare·2026Open Access
Fragment-based discovery reveals unprecedented ligandability and enables direct targeting of the melanoma oncogene MITF
Figshare·2026Open Access
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
Repository for Publications and Research Data (ETH Zurich)·2025Open Access
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
Nature Communications·2025Open Access
Author Correction: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Nature Cancer·2024· 7 citedOpen Access
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Nature·2024· 94 citedOpen Access
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Nature Cancer·2024· 105 citedOpen Access
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas
Nature Cancer·2024· 14 citedOpen Access
Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability
Molecular Cancer Therapeutics·2023· 5 cited
Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations
Cancer Research·2023· 25 cited
Supplementary Table S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Materials and Methods from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Figure S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Table S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Table S3 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
FGF401 characterizing data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Figure S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Table S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
FGF401 characterizing data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
Supplementary Figure S4 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Pascal Furet(10), Karl‐Heinz Altmann(8), Francesco Hofmann(7), Roger J. Davis(6), Paul M.J. McSheehy(6), Christelle Stamm(4), Peter Drueckes(4), Peter R. Allegrini(4), Doriano Fabbro(4), Heidi A. Lane(4), Jürgen Mestan(4), Giorgio Caravatti(4), Terence O’Reilly(4), Jutta Blank(4), William R. Sellers(4), Nancy E. Hynes(4), Dario Sterker(4), Vito Guagnano(3), Vincent Bordas(3), Christian Schnell(3)